Aap Implantate AG Raises EBITDA Forecast

aap Implantate AG has updated its EBITDA guidance, indicating a positive trend for the company's financial performance. The company reported an increase of its EBITDA target for the first nine months of the year. Initially, the forecast ranged from negative EUR 1.5 million to EUR 2.5 million. The updated guidance now suggests a range between negative EUR 0.5 million and positive EUR 0.5 million.

This adjustment reflects a notable improvement, driven by the operating trauma business, despite substantial investments in silver technology. Sales expectations remain between EUR 11.5 million and EUR 13.0 million as previously guided. This update represents a milestone for aap Implantate AG, as it aims to close the financial year profitably at the EBITDA level for the first time within its trauma sector.